People · Operator
Named in public records as an officer, director or promoter · active 2020–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. | — | Biotechnology | Series D+ | $163.4M | $4.0B | 2020 |
Laura J. Stoppel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Laura J. Stoppel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Aslan | 1 | 3 |
| Thomas J. Farrell | 1 | 2 |
| Yong-Jun J. Huh | 1 | 1 |
| Yu-Kyeong J. Hwang | 1 | 1 |
| Jason J. Litten | 1 | 1 |
| Esther J. Van Den Boom | 1 | 1 |
| Bong J. Koh | 1 | 1 |
| Brian J. Daniels | 1 | 1 |
| Peter J. Flynn | 1 | 1 |
| Yvonne J. Yamanaka | 1 | 1 |
| Jennifer J. Bush | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.